Averion Divests Staffing Services Operating Segment.

Company to Focus on Core CRO Offering

SOUTHBOROUGH, Mass. -- Averion International Corp. (OTCBB:AVRO) today announced that it will focus on its core clinical research organization (CRO) business and has sold its staffing services operating segment to members of its management. Under terms of the sale, Averion is due to receive a total consideration of approximately $2.3 million with an upfront cash payment of $455,000, deferred payments totaling $250,000 and unsecured promissory notes with an approximate face value of $1.6 million. The ability of the buyer to make deferred payments and payments under the unsecured promissory notes will be dependent upon the buyer's ability to generate positive future cash flow.

"Our strategy is to enhance our ability to capitalize on the trend toward increased clinical trial outsourcing that is driving industry growth, while taking measures to reach sustainable profitability," said Philip Lavin, PhD, Averion International Chief Executive Officer. "With this transaction, we divest a non-core asset that has been a financial burden on our operations, allowing us to focus our efforts on executing our growth strategies.

"The divestiture of this non-core division is one of many achievements this year that support our corporate goals," he added. Averion's 2007 corporate accomplishments include:

* Cost reduction initiatives that are expected to reduce operating costs by $2.5 million annually and to improve the Company's financial position and operating results;

* Three European office openings to assist in expanding access to larger patient populations and to well-trained personnel to run competitively priced trials;

* Expansion of core oncology competencies and global presence through joint marketing and contract services agreements with India-based CRO Apothecaries Ltd. and Brazil-based CRO BIOCANCER;

* Key executive hires Christopher G. Codeanne as Chief Financial Officer and Glenn E. Deegan as Vice President and General Counsel.

About Averion International Corp.

Averion International Corp. is a full service clinical research organization (CRO) that provides clinical research services to the pharmaceutical, biotechnology and medical device/diagnostic industries. The Company has a therapeutic focus in oncology, medical devices, dermatology and nephrology. Averion's core competencies are in FDA and product registration support, site selection, project management, medical and site monitoring, data management, biometrics, pharmacovigilance, medical writing, and full clinical trial management services throughout the clinical trials lifecycle. The Company has supported FDA approvals for products in many therapeutic areas including: oncology, medical devices, dermatology, and nephrology.

Averion is headquartered in Southborough, Mass. and has an additional U.S. office in New York, as well as European offices in Germany, United Kingdom and Austria, and operations in Poland. For more information, visit www.averionintl.com.

Forward-Looking Statement 

Statements contained in this press release that are not historical information are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "project," or words of similar meaning, or future or conditional verbs such as "will," "would," "should," "could," or "may." Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Those risks and uncertainties include, but are not limited to: our ability to attract, retain or integrate key personnel, including scientific and technical personnel; the termination, modification or delay of contracts which would, among other things, adversely impact our recognition of revenue included in backlog; risks associated with our pursuit of strategic acquisitions or investment in new markets; our ability to acquire and integrate new businesses; our dependence on certain industries and clients; our ability to adequately protect sensitive patient information and confidential information of clients; our ability to keep pace with rapid technological changes; fluctuation in our operating results; our ability to recruit suitable volunteers for the clinical trials of our clients; our exposure to exchange rate fluctuations and international economic, political and other risks; our ability to develop and market new services in the U.S., Europe and internationally; the highly competitive nature of our market; our exposure to changes in outsourcing trends in the pharmaceutical and biotechnology industries; the impact of government regulation on our business; whether we can achieve and maintain effective internal controls; and other risks. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the Company's annual report on Form 10-KSB for the period ending December 31, 2006 and in the Company's other periodic reports filed with the Securities and Exchange Commission. These forward-looking statements are made only as of the date of this press release, and the Company assumes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.